Curis Provides First Quarter 2024 Business Update

Management to host conference call today at 8:30 a.m. ET

LEXINGTON, Mass., May 7, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the first quarter ended March 31, 2024.

Read more at prnewswire.com